8-K: Spero Therapeutics Restructures Operations Following Disappointing Trial Results, Extends Cash Runway

Spero Therapeutics is restructuring its operations, including a 39% workforce reduction, after a Phase 2a trial for SPR720 failed to meet its primary endpoint, but the company has extended its cash runway into mid-2026.

Summary

• Spero Therapeutics announced a restructuring of its operations, including a workforce reduction of approximately 39%.
• This decision follows the failure of the Phase 2a trial of SPR720 for NTM-PD to meet its primary endpoint.
• The company estimates restructuring charges of approximately $1.1 million in cash expenditures.
• Spero's cash and cash equivalents were approximately $76.3 million as of September 30, 2024.
• The restructuring is expected to extend the company's cash runway into mid-2026.
• The company will now focus on the development of tebipenem HBr and SPR206.
• The Phase 3 trial for tebipenem HBr remains on track for enrollment completion in the second half of 2025.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The failure of the SPR720 trial and the subsequent restructuring are negative, but the extended cash runway and focus on tebipenem HBr and SPR206 are positive. The overall sentiment is cautiously negative due to the significant setback with SPR720.

Positives

• The company has extended its cash runway into mid-2026 through restructuring and cost-cutting measures.
• The Phase 3 trial for tebipenem HBr remains on track for enrollment completion in the second half of 2025.
• Spero has a global commercial partnership with GSK for tebipenem HBr, excluding certain Asian territories.
• Spero is eligible for up to $400 million in development, sales, and commercial milestone payments from GSK, as well as tiered royalties.
• SPR206 has shown antibiotic activity against MDR Gram-negative pathogens in preclinical studies.

Negatives

• The Phase 2a trial of SPR720 for NTM-PD failed to meet its primary endpoint.
• The company is suspending its current development program for SPR720.
• The restructuring includes a significant workforce reduction of approximately 39%.
• The company will incur approximately $1.1 million in restructuring charges.
• The estimated cash balance of $76.3 million as of September 30, 2024 is preliminary and may change.

Risks

• The company's cash and cash equivalents as of September 30, 2024 are preliminary and may change materially.
• The restructuring may incur additional costs not currently contemplated.
• The success of tebipenem HBr and SPR206 is subject to regulatory approvals and clinical trial outcomes.
• The company relies on third parties for manufacturing, development, and commercialization.
• The company's cash resources may not be sufficient to fund operations for the anticipated periods.
• There is a risk of slower than anticipated patient enrollment in clinical trials.
• There is a risk of manufacturing challenges and clinical trial design issues.

Future Outlook

Spero expects its existing cash and cash equivalents, along with milestone payments from GSK and other non-dilutive funding, to fund operations into mid-2026. The company will focus on advancing tebipenem HBr and SPR206.

Management Comments

• Sath Shukla, Spero's President and CEO, stated that the SPR720 trial did not meet its primary endpoint despite showing antimicrobial activity.
• Sath Shukla expressed thanks to the Spero SPR720 colleagues, investigators, and patients for their dedication.
• Management remains committed to bringing forward new treatment options for patients in need.

Industry Context

The announcement reflects the challenges in drug development, particularly in the area of novel antibiotics. The failure of the SPR720 trial highlights the high risk and uncertainty associated with clinical trials. The company's focus on tebipenem HBr and SPR206 aligns with the need for new treatments for drug-resistant infections.

Comparison to Industry Standards

• The failure of the SPR720 Phase 2a trial is not uncommon in the pharmaceutical industry, where many drug candidates fail to meet endpoints.
• The restructuring and workforce reduction are typical responses to such setbacks, aimed at preserving capital and focusing on more promising assets.
• The partnership with GSK for tebipenem HBr is a positive sign, as it provides financial support and validation of the drug's potential.
• The focus on oral antibiotics like tebipenem HBr aligns with the industry trend of moving away from intravenous treatments where possible.
• Companies like Meiji Seika, which holds rights to tebipenem HBr in certain Asian territories, are key comparators in the global antibiotic market.

Stakeholder Impact

• Shareholders may experience a negative impact due to the failure of the SPR720 trial and the restructuring.
• Employees will be affected by the workforce reduction.
• Patients may be impacted by the suspension of the SPR720 program, but the company remains committed to developing other treatments.
• GSK, as a partner, will be impacted by the company's strategic shift.

Next Steps

• Spero will complete data analysis of all enrolled patients in the SPR720 trial to determine the next steps for the program.
• The company will continue to advance the Phase 3 PIVOT-PO trial for tebipenem HBr.
• Spero will prepare for a Phase 2 clinical trial for SPR206, contingent on non-dilutive funding.
• The company will implement the workforce reduction and restructuring.

Key Dates

Keywords

Spero Therapeutics, restructuring, workforce reduction, SPR720, tebipenem HBr, SPR206, clinical trial, NTM-PD, cUTI, cash runway, GSK, antibiotics, MDR, Phase 3, Phase 2a